175 related articles for article (PubMed ID: 23018122)
21. Substantia nigra compacta neurons that innervate the reticular thalamic nucleus in the rat also project to striatum or globus pallidus: implications for abnormal motor behavior.
Anaya-Martinez V; Martinez-Marcos A; Martinez-Fong D; Aceves J; Erlij D
Neuroscience; 2006 Dec; 143(2):477-86. PubMed ID: 17008017
[TBL] [Abstract][Full Text] [Related]
22. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat.
Kirik D; Rosenblad C; Björklund A
Exp Neurol; 1998 Aug; 152(2):259-77. PubMed ID: 9710526
[TBL] [Abstract][Full Text] [Related]
23. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages.
Aoi M; Date I; Tomita S; Ohmoto T
Neurosci Res; 2000 Apr; 36(4):319-25. PubMed ID: 10771110
[TBL] [Abstract][Full Text] [Related]
24. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
25. The pesticide fipronil injected into the substantia nigra of male rats decreases striatal dopamine content: A neurochemical, immunohistochemical and behavioral study.
Bharatiya R; Bratzu J; Lobina C; Corda G; Cocco C; De Deurwaerdere P; Argiolas A; Melis MR; Sanna F
Behav Brain Res; 2020 Apr; 384():112562. PubMed ID: 32070689
[TBL] [Abstract][Full Text] [Related]
26. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: motor impairments identify extent of dopamine depletion at three different lesion sites.
Heuer A; Smith GA; Lelos MJ; Lane EL; Dunnett SB
Behav Brain Res; 2012 Mar; 228(1):30-43. PubMed ID: 22146593
[TBL] [Abstract][Full Text] [Related]
27. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
[TBL] [Abstract][Full Text] [Related]
28. Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
Afshin-Majd S; Bashiri K; Kiasalari Z; Baluchnejadmojarad T; Sedaghat R; Roghani M
Biomed Pharmacother; 2017 May; 89():1-9. PubMed ID: 28199883
[TBL] [Abstract][Full Text] [Related]
29. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
Darmopil S; Muñetón-Gómez VC; de Ceballos ML; Bernson M; Moratalla R
Eur J Neurosci; 2008 Feb; 27(3):580-92. PubMed ID: 18279311
[TBL] [Abstract][Full Text] [Related]
30. rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease.
Manfredsson FP; Burger C; Sullivan LF; Muzyczka N; Lewin AS; Mandel RJ
Exp Neurol; 2007 Oct; 207(2):289-301. PubMed ID: 17678648
[TBL] [Abstract][Full Text] [Related]
31. Behavioral and neurophysiological correlates of striatal dopamine depletion: a rodent model of Parkinson's disease.
Plowman EK; Kleim JA
J Commun Disord; 2011; 44(5):549-56. PubMed ID: 21601869
[TBL] [Abstract][Full Text] [Related]
32. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity.
Gaugler MN; Genc O; Bobela W; Mohanna S; Ardah MT; El-Agnaf OM; Cantoni M; Bensadoun JC; Schneggenburger R; Knott GW; Aebischer P; Schneider BL
Acta Neuropathol; 2012 May; 123(5):653-69. PubMed ID: 22361813
[TBL] [Abstract][Full Text] [Related]
33. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
34. Role of dopamine in the recruitment of immune cells to the nigro-striatal dopaminergic structures.
Espinosa-Oliva AM; de Pablos RM; Sarmiento M; Villarán RF; Carrillo-Jiménez A; Santiago M; Venero JL; Herrera AJ; Cano J; Machado A
Neurotoxicology; 2014 Mar; 41():89-101. PubMed ID: 24486959
[TBL] [Abstract][Full Text] [Related]
35. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
36. High frequency stimulation of subthalamic nucleus results in behavioral recovery by increasing striatal dopamine release in 6-hydroxydopamine lesioned rat.
He Z; Jiang Y; Xu H; Jiang H; Jia W; Sun P; Xie J
Behav Brain Res; 2014 Apr; 263():108-14. PubMed ID: 24462728
[TBL] [Abstract][Full Text] [Related]
37. Amphetamine-evoked rotation requires newly synthesized dopamine at 14 days but not 1 day after intranigral 6-OHDA and is consistently dissociated from sensorimotor behavior.
Paquette MA; Marsh ST; Hutchings JE; Castañeda E
Behav Brain Res; 2009 Jun; 200(1):197-207. PubMed ID: 19378464
[TBL] [Abstract][Full Text] [Related]
38. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat.
Lee CS; Sauer H; Bjorklund A
Neuroscience; 1996 Jun; 72(3):641-53. PubMed ID: 9157311
[TBL] [Abstract][Full Text] [Related]
39. Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson's disease.
Chen HH; Chang PC; Chen C; Chan MH
Pharmacol Rep; 2018 Aug; 70(4):668-676. PubMed ID: 29909247
[TBL] [Abstract][Full Text] [Related]
40. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease.
Kirik D; Georgievska B; Rosenblad C; Björklund A
Eur J Neurosci; 2001 Apr; 13(8):1589-99. PubMed ID: 11328352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
